FrancophonIA/ELRC3.0 huggingface dataset:
English: • Although no specific data about the cardiovascular risk with dexibuprofen are available, a similar cardiovascular risk to that with high-dose of ibuprofen is expected when dexibuprofen is used at equipotent doses (at or above 1,200 mg per day).
Slovenian: • Kljub temu da niso na voljo nobeni specifični podatki o srčno-žilnem tveganju, povezanem z deksibuprofenom, je mogoče pričakovati podobno srčno-žilno tveganje pri uporabi velikih odmerkov ibuprofena in odmerkov deksibuprofena enakih jakosti (1200 mg na dan ali več).
English: The review also looked at data on the interaction between ibuprofen and low-dose aspirin when the latter is taken to reduce the risk of heart attacks and strokes.
Slovenian: V okviru pregleda so proučili tudi podatke o medsebojnem delovanju ibuprofena in nizkoodmernega aspirina, ki se jemlje za zmanjšanje tveganja za srčne in možganske kapi.
English: • An EU-wide review of ibuprofen has confirmed that there is a small risk of heart attacks and strokes in patients taking high doses of the medicine (at or above 2,400 mg per day).
Slovenian: • Pregled ibuprofena po vsej EU je potrdil, da obstaja majhno tveganje za srčne in možganske kapi pri bolnikih, ki jemljejo velike odmerke zdravila (2400 mg na dan ali več).
English: As the CMDh has now agreed the PRAC advice by consensus, changes to the product information for ibuprofen- and dexibuprofen-containing medicines will be implemented by the Member States where the medicines are authorised, according to an agreed timetable.
Slovenian: Ker se je skupina CMDh soglasno strinjala s priporočili odbora PRAC, bodo države članice, v katerih so zdravila odobrena, spremenile informacije o zdravilu za zdravila, ki vsebujejo ibuprofen in deksibuprofen, v skladu z dogovorjenim časovnim razporedom.
English: This follows a review carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed a small increased risk of cardiovascular problems, such as heart attacks and strokes, in patients taking high doses of ibuprofen (at or above 2,400 mg per day).
Slovenian: Podlaga je bila pregled, ki ga je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC) pri Evropski agenciji za zdravila in ki je potrdil rahlo povečano tveganje za srčno-žilne zaplete, kot so srčne in možganske kapi, pri bolnikih, ki jemljejo velike odmerke ibuprofena (2400 mg na dan ali več).
English: No risk has been seen with ibuprofen at doses up to 1,200 mg per day, which is the highest dose usually taken by the majority of patients.
Slovenian: Pri uporabi odmerkov ibuprofena do 1200 mg na dan, kar je največji odmerek, ki ga običajno jemlje večina bolnikov, tveganja niso opazili.
English: No clinically relevant effect is considered to be likely for occasional ibuprofen use.
Slovenian: Pri občasni uporabi ibuprofena ni pričakovati klinično pomembnega vpliva.
English: • Data from meta-analyses and epidemiological studies indicate that there is an increased risk of cardiovascular events (such as myocardial infarction or stroke) associated with the use of highdose ibuprofen (at or above 2,400 mg per day).1-4
Slovenian: • Podatki iz metaanaliz in epidemioloških študij kažejo, da je z uporabo velikih odmerkov ibuprofena (2400 mg na dan ali več) povezano povečano tveganje za srčno-žilne dogodke (kot sta srčni infarkt in možganska kap).1-4
English: It followed concerns that high doses of ibuprofen could have a similar cardiovascular risk to that of COX-2 inhibitors and diclofenac.
Slovenian: Pregled je bil sprožen zaradi zaskrbljenosti, da bi veliki odmerki ibuprofena lahko bili povezani s podobnim srčno-žilnim tveganjem kot zaviralci COX-2 in diklofenak.
English: • The risk with high-dose ibuprofen is similar to the risk seen with some other non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac.
Slovenian: • Tveganje pri uporabi velikih odmerkov ibuprofena je podobno tveganju, ki ga opažajo pri uporabi nekaterih drugih nesteroidnih protivnetnih zdravil, med drugim zaviralcev COX-2 in diklofenaka.
English: You should therefore always seek the advice of your doctor or pharmacist before using ibuprofen with aspirin.
Slovenian: Preden uporabite ibuprofen skupaj z aspirinom, se zato vedno posvetujte z zdravnikom ali s farmacevtom.
English: No increase in cardiovascular risk is seen with ibuprofen at doses of up to 1,200 mg per day, which is the highest dose generally used for over-the-counter (OTC) preparations taken by mouth in the European Union (EU).
Slovenian: Povečanega srčno-žilnega tveganja pa niso opazili pri uporabi ibuprofena v odmerkih do 1200 mg na dan, kar je največji odmerek, ki se običajno uporablja v EU pri farmacevtskih oblikah, ki se jemljejo peroralno in se izdajajo brez recepta.
English: The safety of NSAIDs, including ibuprofen, has been reviewed regularly by authorities in the EU over the past few years.
Slovenian: Zadnjih nekaj let organi v EU redno ocenjujejo varnost nesteroidnih protivnetnih zdravil, med drugim tudi ibuprofena.
English: The review clarifies that the risk with highdose ibuprofen is similar to the risk seen with some other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac.
Slovenian: Pregled je pokazal, da je tveganje pri uporabi velikih odmerkov ibuprofena podobno tveganju, ki ga opažajo pri uporabi nekaterih drugih nesteroidnih protivnetnih zdravil, med drugim zaviralcev COX-2 in diklofenaka.
English: Long-term cardiovascular risk of nonsteroidal antiinflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study.
Slovenian: Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal antiinflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study.
English: This summary was last updated in 05-2009.
Slovenian: Ta povzetek je bil nazadnje posodobljen 05-2009.
English: It is available as capsules (yellow: 1.5 mg, orange: 3 mg, brownish red: 4.5 mg, and brownish red and orange: 6 mg) and as white orodispersible tablets (1.5 mg, 3 mg, 4.5 mg, and 6 mg).
Slovenian: Na voljo je v obliki kapsul (rumenih: 1,5 mg, oranžnih: 3 mg, rjavkasto rdečih: 4,5 mg in rjavkasto rdečih in oranžnih: 6 mg) ter v obliki belih orodisperzibilnih tablet (1,5 mg, 3 mg, 4,5 mg in 6 mg).
English: Other information about Nimvastid:
Slovenian: Druge informacije o zdravilu Nimvastid:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nimvastid to KRKA,d.d., Novo mesto on 11 May 2009.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Nimvastid, veljavno po vsej Evropski uniji, odobrila družbi KRKA,d.d., Novo mesto dne 11. maja 2009.
English: This means that Nimvastid is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Slovenian: To pomeni, da je zdravilo Nimvastid podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
English: The Committee recommended that Nimvastid be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Nimvastid odobri dovoljenje za promet.
English: What are the benefit and risk of Nimvastid?
Slovenian: Kakšne so koristi in tveganja, povezana z zdravilom Nimvastid?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NIMVASTID EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NIMVASTID Povzetek EPAR za javnost
English: The starting dose for Nimvastid is 1.5 mg twice a day.
Slovenian: Začetni odmerek zdravila Nimvastid je 1,5 mg dvakrat na dan.
English: Nimvastid is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Slovenian: Zdravilo Nimvastid se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
English: Why has Nimvastid been approved?
Slovenian: Zakaj je bilo zdravilo Nimvastid odobreno?
English: Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.
Slovenian: Zdravljenje je treba nadaljevati, dokler je zdravilo učinkovito, vendar se lahko odmerek zniža in zdravljenje prekine, če se pri bolniku pojavijo neželeni učinki.
English: Treatment with Nimvastid should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Slovenian: Zdravljenje z zdravilom Nimvastid mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
English: Nimvastid is a ‘generic medicine'.
Slovenian: Zdravilo Nimvastid je „generično zdravilo“.
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nimvastid has been shown to have comparable quality and to be bioequivalent to Exelon.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Nimvastid primerljivo raven kakovosti kot zdravilo Exelon ter da mu je biološko enakovredno.
English: Nimvastid orodispersible tablets should be placed on the tongue, where they disintegrate quickly in the saliva before being swallowed.
Slovenian: Orodisprezibilne tablete Nimvastid se položijo na jezik, kjer se v slini hitro razgradijo, preden jih bolnik pogoltne.
English: Because Nimvastid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Slovenian: Glede na to, da je Nimvastid generično zdravilo in je bioekvivalentno referenčnemu zdravilu, ima enake koristi in tveganja kot referenčno zdravilo.
English: Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
Slovenian: Rivastigmin deluje tako, da zavira encime, ki razgrajujejo acetilholin: acetilholinesterazo in butirilholinesterazo.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Nimvastid by the patient.
Slovenian: Zdravljenje se začne samo ob prisotnosti negovalca, ki redno nadzoruje uporabo zdravila Nimvastid pri bolniku.
English: Because Nimvastid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).
Slovenian: Ker je zdravilo Nimvastid generično zdravilo, so bile študije omejene na preskuse, s katerimi se dokazuje, da je biološko enakovredno referenčnemu zdravilu (tj. da zdravili dosegata enake ravni zdravilne učinkovine v telesu).
English: It is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Slovenian: Zdravilo se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s parkinsonovo boleznijo.
English: By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Slovenian: Zdravilo Nimvastid z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
English: Orodispersible means that the tablets dissolve in the mouth.
Slovenian: Orodisperzibilne tablete so tablete, ki se raztopijo v ustih.
English: Nimvastid is a medicine that contains the active substance rivastigmine.
Slovenian: Nimvastid je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
English: In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Slovenian: Pri bolnikih, ki prenašajo ta odmerek, se lahko ta postopoma povečuje za 1,5 mg, vendar ne pogosteje kot vsaka dva tedna, dokler se ne doseže stalnega odmerka 3 do 6 mg dvakrat na dan. Za dosego največje učinkovitosti se uporabi največji odmerek, ki ga bolnik še prenaša, vendar odmerek ne sme preseči 6 mg dvakrat na dan.
English: The active substance in Nimvastid, rivastigmine, is an antidementia medicine.
Slovenian: Zdravilna učinkovina zdravila Nimvastid je rivastigmin, ki je zdravilo za zdravljenje demence.
English: resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other).
Slovenian: Pri bolnikih z alzheimerjevo demenco ali demenco zaradi parkinsonove bolezni v možganih odmrejo določene živčne celice, zaradi česar se znižajo ravni nevrotransmiterja acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo med živčnimi celicami).
English: The full EPAR for Nimvastid can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Nimvastid je na voljo tukaj.
English: Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk.
Slovenian: Zato je CHMP menil, da koristi zdravila Nimvastid, tako kot pri zdravilu Exelon, odtehtajo znana tveganja.
English: What is Nimvastid?
Slovenian: Kaj je zdravilo Nimvastid?
English: How is Nimvastid used?
Slovenian: Kako se zdravilo Nimvastid uporablja?
English: What is Nimvastid used for?
Slovenian: Za kaj se zdravilo Nimvastid uporablja?
English: How has Nimvastid been studied?
Slovenian: Kako je bilo zdravilo Nimvastid raziskano?
English: How does Nimvastid work?
Slovenian: Kako zdravilo Nimvastid deluje?
English: Nimvastid should be given twice a day, with morning and evening meals.
Slovenian: Zdravilo Nimvastid se daje dvakrat na dan, ob zajtrkih in večerjah.
English: months).
Slovenian: (približno 10 mesecev).
English: This summary was last updated in 09-2011.
Slovenian: Povzetek je bil nazadnje posodobljen 09-2011.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 22 May 2008.
Slovenian: Ker je družba predložila zahtevane dodatne informacije, so „izjemne okoliščine“ prenehale veljati 22. maja 2008.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zevalin on 16 January 2004.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zevalin, veljavno po vsej Evropski uniji, odobrila dne 16. januarja 2004.
English: Zevalin was originally authorised under ‘exceptional circumstances' because it had not been possible to obtain complete information about Zevalin.
Slovenian: Zdravilo Zevalin je bilo prvotno odobreno v „izjemnih okoliščinah“, ker ni bilo mogoče pridobiti vseh informacij o njem.
English: The full EPAR for Zevalin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zevalin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: However, the time taken for the disease to get worse after treatment was the same in both groups (about 10
Slovenian: Vendar pa je bil čas do poslabšanja bolezni po zdravljenju v obeh skupinah enak
English: The doctor who prescribes it must ensure that the risks linked to the exposure to the radioactivity are lower than the risks from the disease itself.
Slovenian: Zdravnik, ki ga predpiše, se mora prepričati, da so tveganja zaradi izpostavljenosti radioaktivnosti manjša od tveganj, ki izhajajo iz same bolezni.
English: Zevalin must be given as a slow infusion lasting 10 minutes.
Slovenian: Zdravilo Zevalin je treba dajati kot počasno infuzijo v trajanju 10 minut.
English: Other information about Zevalin
Slovenian: Druge informacije o zdravilu Zevalin
English: This is a summary of the European public assessment report (EPAR) for Zevalin.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zevalin.
English: For more information about treatment with Zevalin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Zevalin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: The main measure of effectiveness was the length of time the patients survived without their disease getting worse.
Slovenian: Glavno merilo učinkovitosti je bil čas preživetja bolnika brez poslabšanja bolezni.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells in the body.
Slovenian: Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna posebno strukturo (imenovano antigen), ki jo najdemo v določenih celicah v telesu, in se veže nanjo.
English: EPAR summary for the public ibritumomab tiuxetan
Slovenian: Povzetek EPAR za javnost ibritumomab tiuksetan
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zevalin.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zevalin, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: What benefit has Zevalin shown during the studies?
Slovenian: Kakšne koristi je zdravilo Zevalin izkazalo med študijami?
English: In both studies, the main measure of effectiveness was the number of patients whose disease responded partially or completely to treatment.
Slovenian: V vseh študijah je bilo glavno merilo učinkovitosti število bolnikov s popolnim ali delnim odzivom na zdravljenje.
English: The study compared patients who received Zevalin and patients who received no additional treatment.
Slovenian: V študiji so primerjali bolnike, ki so prejeli Zevalin, in bolnike, ki niso prejeli nobenega dodatnega zdravljenja.
English: In the additional study, radiolabelled Zevalin brought about a response in about half of the patients.
Slovenian: Pri dodatni študiji je radioaktivno označeno zdravilo Zevalin povzročilo odziv pri približno polovici bolnikov.
English: However, there were too few patients who had received rituximab as part of their induction treatment to determine whether there would be a benefit of using Zevalin as consolidation treatment in these patients.
Slovenian: Vendar je premalo bolnikov prejelo rituksimab kot del indukcijskega zdravljenja, da bi lahko določili, ali bi jim uporaba zdravila Zevalin kot konsolidacijskega zdravljenja koristila.
English: This is followed, seven to nine days later, by a second infusion of rituximab and an injection of radiolabelled Zevalin.
Slovenian: Sedem do devet dni kasneje temu sledi nova infuzija rituksimaba in injekcija radioaktivno označenega zdravila Zevalin.
English: Zevalin should not be used in people who may be hypersensitive (allergic) to ibritumomab, yttrium chloride, mouse proteins or any of the other ingredients.
Slovenian: Zdravila Zevalin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ibritumomab, itrijev klorid, mišje beljakovine ali katero koli drugo sestavino zdravila.
English: Ibritumomab has been designed to target an antigen, CD20, which is present on the surface of all B lymphocytes.
Slovenian: Ibritumomab je bil zasnovan tako, da se veže na antigen CD20, ki je prisoten na površini vseh limfocitov B.
English: What is the risk associated with Zevalin?
Slovenian: Kakšna tveganja so povezana z zdravilom Zevalin?
English: Radiolabelled Zevalin treatment should only be handled and given by someone who is authorised to use radioactive medicines.
Slovenian: Z radioaktivno označenim zdravilom Zevalin smejo rokovati in ga dajati samo osebe, pooblaščene za uporabo radioaktivnih zdravil.
English: Zevalin is not used directly, but it must be radiolabelled before use.
Slovenian: Zdravilo Zevalin se ne uporablja neposredno, temveč ga je treba pred uporabo radioaktivno označiti.
English: In patients who were not responding to other treatments or whose disease had come back after previous treatment, Zevalin was more effective than rituximab: 80% of the patients receiving radiolabelled Zevalin responded, compared with 56% of the patients receiving rituximab.
Slovenian: Pri bolnikih, ki se niso odzivali na druga zdravljenja ali pri katerih se je bolezen po predhodnem zdravljenju ponovila, je bilo zdravilo Zevalin učinkovitejše od rituksimaba: odzvalo se je 80 % bolnikov, ki so prejemali radioaktivno označeno zdravilo Zevalin, v primerjavi s 56 % bolnikov, ki so prejemali rituksimab.
English: When Zevalin was used as consolidation therapy, patients survived for longer without their disease getting worse than when they received no further treatment.
Slovenian: Ko se je zdravilo Zevalin uporabilo kot konsolidacijska terapija, so bolniki preživeli dlje časa brez poslabšanja bolezni, kot če niso prejeli nobenega nadaljnjega zdravljenja.
English: Patients receiving radiolabelled Zevalin survived for an average of 37 months until their disease got worse, compared with 14 months in those who did not receive any further treatment.
Slovenian: Bolniki, ki so prejemali radioaktivno označeno zdravilo Zevalin, so v povprečju preživeli 37 mesecev do poslabšanja bolezni, v primerjavi s 14 meseci pri tistih bolnikih, ki niso prejemali nobenega nadaljnjega zdravljenja.
English: The dose of Zevalin is calculated to give the appropriate amount of radioactivity for the patient's condition, based on the blood cell count.
Slovenian: Odmerek zdravila Zevalin se izračuna tako, da bolniku zagotovi ustrezno količino radioaktivnosti glede na njegovo stanje, ugotovljeno na podlagi števila krvnih celic.
English: The Committee recommended that Zevalin be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Zevalin odobri dovoljenje za promet.
English: Radiolabelled Zevalin is radioactive and its use may carry a risk of cancer and hereditary defects.
Slovenian: Radioaktivno označeno zdravilo Zevalin je radioaktivno, njegova uporaba pa lahko pomeni tveganje za razvoj raka in dednih okvar.
English: Zevalin must not be used in patients who are pregnant or breast feeding.
Slovenian: Ne smejo ga uporabljati bolnice, ki so noseče ali dojijo.
English: For consolidation therapy, Zevalin has been studied in one main study involving 414 patients who had achieved a partial or complete remission during induction treatment for non Hodgkin's lymphoma.
Slovenian: Pri konsolidacijski terapiji so zdravilo Zevalin proučevali v eni glavni študiji, v katero je bilo vključenih 414 bolnikov, ki so dosegli delno ali popolno remisijo med indukcijskim zdravljenjem ne-Hodgkinovega limfoma.
English: The most common side effects with Zevalin (seen in more than 1 patient in 10) are anaemia (low red blood cell counts), leucocytopenia and neutropenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), asthenia (weakness), pyrexia (fever), rigors (stiffness) and nausea (feeling sick).
Slovenian: Najpogostejši neželeni učinki zdravila Zevalin (opaženi pri več kot 1 bolniku od 10) so slabokrvnost (nizka koncentracija rdečih krvničk), levkocitopenija in nevtropenija (nizka koncentracija belih krvničk), trombocitopenija (nizka koncentracija trombocitov), astenija (splošna oslabelost), pireksija (povišana telesna temperatura), rigor (okorelost) in navzeja (slabost).
English: For the full list of all side effects reported with Zevalin, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zevalin, glejte navodilo za uporabo.
English: The active substance in Zevalin, ibritumomab, is a monoclonal antibody.
Slovenian: Zdravilna učinkovina zdravila Zevalin, ibritumomab, je monoklonsko protitelo.